Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of beta-3 agonist YM178 (DRAGON) in overactive bladder
2005-002256-17Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mirabegron in overactive bladder (OAB) (3 arms), sponsored by Astellas Pharma. Primary endpoints: Efficacy dose-response of YM178-OCAS and Safety and tolerability of YM178-OCAS. Started Nov 2005; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-002256-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002256-17.